EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Molecular Mechanisms of Synergistic Effect of PRIMA ‐1 met and Oxaliplatin in Colorectal Cancer With Different p53 Status

Xiao-Lan Li iD, Jianbiao Zhou, Nicole Xin-Ning Tang, Yi Chai, Meng Zhou, Ai-di Gao, Zhong-Kai Lu, Han Min iD

Cancer Medicine · 2025

DOI: 10.1002/cam4.70530 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Xiao-Lan Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, Jiangsu, People's Re…. Hauptthemen laut MEDLINE: Oxaliplatin, Colorectal Neoplasms, Tumor Suppressor Protein p53, Drug Synergism. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Suzhou Municipal Science and Technology Bureau.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The toxicity and drug resistance associated with oxaliplatin (L‐OHP) limit its long‐term use for colorectal cancer (CRC) patients. p53 mutation is a common genetic trait of CRC. PRIMA‐1 met (APR‐246, eprenetapopt) restores the DNA‐binding capacity of different mutant P53 proteins. PRIMA‐1 met has progressed to the Phase III clinical trial. Our study explores the combination therapy of PRIMA‐1 met and L‐OHP for CRC with different p53 status.

Methods

Cell viability was assessed with Cell Counting Kit‐8 (CCK‐8) assay and combination index (CI) was calculated using The Chou‐Talalay method. We also employed wound healing assay and colony formation assay to determine the effect of L‐OHP, PRIMA‐1 met and their combination. Weighted gene co‐expression network analysis (WGCNA) of RNA‐seq data was conducted to identify key modules and central genes related to different treatment modalities. Xenograft CRC mouse model was used to assess the combination treatment in vivo.

Results

Our findings showed heightened cytotoxicity and inhibition of migration, and colony formation in CRC cells treated with both drugs, irrespective of p53 status, presenting a promising avenue for addressing L‐OHP resistance and toxicity. RNA‐seq analysis revealed differential responses between p53‐wide type HCT116 and p53‐mutant DLD‐1 cells, with pathway alterations implicated in tumorigenesis. WGCNA identified key modules and hub genes associated with combination therapy response. In vivo studies demonstrated enhanced efficacy of combined therapy over PRIMA‐1 met alone, while mitigating L‐OHP‐induced toxicity.

Conclusions

In summary, our research reveals the differential molecular mechanisms of combined PRIMA‐1 met and L‐OHP in CRC with wild type p53 and mutant p53. Our data not only demonstrate that this combined regimen exerts synergistic anti‐CRC effect in vitro and in vivo, but also suggest the benefit of PRIMA‐1 met on prevention of L‐OHP‐related side effects. These findings underscore the clinical potential of PRIMA‐1 met ‐L‐OHP combination therapy in CRC, offering enhanced efficacy and reduced toxicity, warranting further clinical investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OxaliplatinColorectal NeoplasmsTumor Suppressor Protein p53Drug SynergismXenograft Model Antitumor AssaysAntineoplastic Combined Chemotherapy ProtocolsHumansAnimalsMiceQuinuclidinesCell Line, TumorMice, NudeCell ProliferationHCT116 CellsCell SurvivalMutationGene Expression Regulation, NeoplasticFemale

Stichwörter der Autor:innen

PRIMA‐1metcolorectal cancer (CRC)combination therapydrug resistancehematologic toxicityoxaliplatin (L‐OHP)p53 tumor suppressor gene

Substanzen

OxaliplatinTumor Suppressor Protein p53eprenetapoptTP53 protein, humanQuinuclidines

Autor:innen und Institutionen

  • Department of Gastroenterology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, Jiangsu, People's Republic of China.
  • Cancer Science Institute of Singapore, National University of Singapore, Singapore.
  • Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
  • NUS Centre for Cancer Research, National University of Singapore, Singapore.
  • Changzhou No. 4 People's Hospital, Changzhou City, Jiangsu Province, People's Republic of China.

ORCID-Profile: Xiao-Lan Li, Han Min

Förderung

  • National Natural Science Foundation of China
  • Suzhou Municipal Science and Technology Bureau

Zitieren

APA

Li, X. L., Zhou, J., Tang, N. X., Chai, Y., Zhou, M., Gao, A. D., Lu, Z. K., & Min, H. (2025). Molecular Mechanisms of Synergistic Effect of PRIMA ‐1 met and Oxaliplatin in Colorectal Cancer With Different p53 Status. Cancer Medicine. https://doi.org/10.1002/cam4.70530

Vancouver

Li XL, Zhou J, Tang NX, Chai Y, Zhou M, Gao AD, et al. Molecular Mechanisms of Synergistic Effect of PRIMA ‐1 met and Oxaliplatin in Colorectal Cancer With Different p53 Status. Cancer Medicine. 2025. doi:10.1002/cam4.70530

BibTeX
@article{Li2025,
  author = {Li, Xiao-Lan and Zhou, Jianbiao and Tang, Nicole Xin-Ning and Chai, Yi and Zhou, Meng and Gao, Ai-di and Lu, Zhong-Kai and Min, Han},
  title = {Molecular Mechanisms of Synergistic Effect of PRIMA ‐1 met and Oxaliplatin in Colorectal Cancer With Different p53 Status},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.70530}
}
Kostenlos starten →